Skip to content

Sclerotherapy of Internal Spermatic Veins in Patients With Varicocele and Localized Prostate Cancer

Selective Retrograde Venography and Sclerotherapy of Internal Spermatic Veins and Associated Venous Bypasses and Retro-Peritoneal Collateral in Patients With Bilateral Varicocele and Localized Prostate Cancer

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00637208
Enrollment
10
Registered
2008-03-17
Start date
2007-11-30
Completion date
2008-03-31
Last updated
2008-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Keywords

prostate cancer, venography, male patients, Localized microscopic prostate cancer up to Gleason 6 (3+3), PSA level <14, presence of varicocele

Brief summary

Patients with varicocele in whon early prostate cancer will be found will undergo venographic embolization of both spermatic veins. The study hypothesis is that this procedure will induce a gradual regression of the prostate volume that may decrease prostate cancer cells. Close follow-up will ensure that necessary therapy will be provided if needed according to clinical criteria. Results in terms of prostate size PSA level and tumor size will be recorded.

Interventions

PROCEDUREvenographic occlusion of spermatic veins

Through the femoral vein a catheter is inserted into the spermatic veins in succession and the veins are occluded.

Sponsors

Maaynei Hayesha Medical Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
45 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Males age 45-75 * Prostate cancer * Presence of varicocele * No contraindication for venography

Exclusion criteria

* Diseases or medications which prevent interventional vascular procedures

Design outcomes

Primary

MeasureTime frame
Safety performance of the procedure. The change in tumor size and prostate cancer cells as evaluated by trans-rectal ultrasound and prostate biopsyone year

Secondary

MeasureTime frame
The change in size of the prostate as evaluated by ultrasound Change in PSA value. Reduction of above 20% in nocturiaone year

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026